Kita T, Ishii K, Yokode M, Kume N, Nagano Y, Arai H, Kawai C
Department of Geriatric Medicine, Faculty of Medicine, Kyoto University, Japan.
Eur Heart J. 1990 Aug;11 Suppl E:122-7. doi: 10.1093/eurheartj/11.suppl_e.122.
Recently, it has been suggested that oxidized low density lipoprotein (LDL) plays an important role in atherogenesis by facilitating the accumulation of lipids in macrophages. In vitro studies from our laboratory have shown that oxidized LDL is recognized not only by a specific receptor, but also by a receptor which recognizes both oxidized LDL and acetyl LDL. Probucol, originally developed as an antioxidant, prevents the oxidative modification of LDL in vitro. Our recent studies show that probucol prevents the progression of atherosclerosis in homozygous WHHL rabbits in vivo without any changes in plasma LDL cholesterol levels. These results strongly suggest that oxidative modification of LDL could occur in vivo and probucol could slow the progression of atherosclerosis, especially the foam cell-rich fatty streak lesions, without changing plasma cholesterol levels.
最近,有人提出氧化型低密度脂蛋白(LDL)通过促进脂质在巨噬细胞中的积累,在动脉粥样硬化形成过程中发挥重要作用。我们实验室的体外研究表明,氧化型LDL不仅能被一种特异性受体识别,还能被一种既识别氧化型LDL又识别乙酰化LDL的受体识别。普罗布考最初作为一种抗氧化剂开发,在体外可防止LDL的氧化修饰。我们最近的研究表明,普罗布考在体内可阻止纯合子WHHL兔动脉粥样硬化的进展,而血浆LDL胆固醇水平无任何变化。这些结果有力地表明,LDL的氧化修饰可能在体内发生,普罗布考可减缓动脉粥样硬化的进展,尤其是富含泡沫细胞的脂纹病变,而不改变血浆胆固醇水平。